Black Rock Inc. Myovant Sciences Ltd. Transaction History

Black Rock Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$24.03 - $27.02 $86,219 - $96,947	-3,588 Reduced 0.3%	1,182,942 $31.9 Million
Q3 2022 Nov 14, 2022	BUY	$11.6 - $20.44 $988,227 - $1.74 Million	85,192 Added 7.74%	1,186,530 $21.3 Million
Q2 2022 Aug 12, 2022	SELL	$7.78 - $14.69 $790,735 - $1.49 Million	-101,637 Reduced 8.45%	1,101,338 $13.7 Million
Q1 2022 May 12, 2022	BUY	$11.38 - $16.4 $467,570 - $673,826	41,087 Added 3.54%	1,202,975 $16 Million
Q4 2021 Feb 10, 2022	BUY	$14.31 - $23.87 $375,680 - $626,659	26,253 Added 2.31%	1,161,888 $18.1 Million
Q3 2021 Nov 09, 2021	BUY	$18.94 - $26.99 $1.46 Million - $2.09 Million	77,322 Added 7.31%	1,135,635 $25.5 Million
Q2 2021 Aug 11, 2021	BUY	$17.07 - $24.56 $18.1 Million - $26 Million	1,058,313 New	1,058,313 $24.1 Million

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.